Patients from 22+ countriesPlan your visit →
lutetium-therapy
Second Opinions · 7 Sept 2026

How to Get a PRRT Second Opinion Before Travelling to India

Before you book a flight to India for PRRT, a remote Ga-68 DOTATATE eligibility review can tell you whether you are likely to qualify - and what to do if you are not. Here is what the process involves and what documents you need.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 7 Sept 2026
How to Get a PRRT Second Opinion Before Travelling to India

If you have a gastroenteropancreatic neuroendocrine tumor (GEP-NET) and are wondering if PRRT is your next step, this article is for you. It's written for patients considering lutetium Lu-177 dotatate (brand name Lutathera) for advanced GEP-NET. You may know that India offers this treatment for less money than the US, UK, or GCC countries, and that experienced centers are there. Before you book a trip, you need to know whether you're actually a good candidate for the treatment. A remote eligibility review using your existing scans and records can help answer that.

What Is a Remote PRRT Eligibility Review?

A remote PRRT eligibility review is when a specialist nuclear-medicine team looks at your existing scans, pathology results, and blood tests. You share your digital files. The team reviews them and gives you a written clinical opinion on whether your case is likely to meet the requirements for lutetium Lu-177 dotatate.

According to the Neuroendocrine Tumor Research Foundation, PRRT works by attaching a radioactive particle to a molecule that looks for somatostatin receptors on NET cells. Patients whose tumors show strong receptor uptake on a Ga-68 DOTATATE PET/CT scan are most likely to benefit. That scan is the key part of any eligibility review - whether remote or in-person.

This differs from a routine referral to another local oncologist. It's a review by a PRRT-experienced team who can read your scan using the same criteria applied in clinical practice - criteria that may not be clear to patients whose main team has limited experience with theranostics or radioligand therapy.

Why Get a Second Opinion Before You Travel?

Not every NET patient is eligible for PRRT. The most important requirement is strong somatostatin receptor expression, confirmed by imaging. If that expression is low or absent, lutetium Lu-177 dotatate will not reach and treat your disease effectively - and a specialist center in India would reach the same conclusion when you arrive.

A remote review lets you know this before you spend money on visas, flights, and accommodation. It can also flag other factors that might delay or prevent treatment: borderline kidney function, low blood counts from prior chemotherapy, or disease that has changed since your last scan. For patients managing GEP-NET symptoms like fatigue, flushing, or loose stools from carcinoid syndrome, an unnecessary long trip is difficult.

A second clinical opinion also gives your home oncologist something concrete to work with - an independent view from a team with focused PRRT experience. This detail is often more helpful than a general second opinion from an oncologist who does not specialize in theranostics.

What Does a Remote Review Need From You?

You do not need to send everything at once to get a first opinion. Your Ga-68 DOTATATE PET report and pathology report together are usually enough to start. A complete review typically uses:

  1. Ga-68 DOTATATE PET/CT scan - full DICOM images, or a detailed radiology report with SUVmax values and Krenning score
  2. Histopathology report - including Ki-67 index and NET grade (G1, G2, or G3)
  3. Recent contrast CT or MRI - covering the abdomen, chest, and pelvis, ideally from the past three to six months
  4. Blood tests - a full blood count, kidney function (creatinine and eGFR), and a liver function panel
  5. Short treatment history - what therapies you have had, how your disease responded, and when your most recent treatment ended
  6. FDG-PET result, if you have one - high FDG uptake can suggest more aggressive disease behavior that may affect PRRT candidacy

Most centers that treat international patients accept files through a secure online portal, by encrypted email, or as a tracked courier package for CD-based imaging. A written radiology summary with SUVmax values, Krenning score, and a brief clinical history is usually enough for a first opinion without sending large image files. Patients from the GCC, East Africa, and South Asia regularly start the review process this way before deciding whether to make the journey.

If your Ga-68 DOTATATE PET is more than twelve months old, or if your disease has progressed since that scan, fresh imaging may be needed before the team can give a reliable opinion. To understand how this scan works in practice, the article on how Ga-68 DOTATATE PET determines your PRRT eligibility explains the scan itself in plain language.

How the Review Team Reads Your Case

The Krenning score. This is a 0 to 4 scale that grades how strongly your tumor absorbs the DOTATATE tracer during the PET scan. A score of 0 or 1 means little to no uptake. A score of 3 or 4 - uptake clearly stronger than normal liver tissue - is the threshold most experienced PRRT centers prefer before starting treatment. The landmark NETTER-1 phase 3 trial, which compared lutetium Lu-177 dotatate against high-dose octreotide LAR in patients with progressive midgut NETs, required a Krenning score of at least 2 for study entry and found significantly longer progression-free survival in the lutetium-treated group. A score of 2 is in a gray zone. A remote review team can interpret a borderline result by looking at how many lesions are DOTATATE-avid and what the FDG scan shows.

Ki-67 grade. Ki-67 is a protein marker in your pathology report that shows how fast your tumor cells are dividing. For PRRT, the grade matters:

  • Grade 1 (Ki-67 under 3%): typically somatostatin-receptor-positive and well suited to PRRT
  • Grade 2 (Ki-67 between 3% and 20%): generally suitable, and the most common group in PRRT clinical practice
  • Grade 3 (Ki-67 between 21% and 55%): a more complicated picture - may still qualify depending on DOTATATE uptake and FDG results
  • Ki-67 above 55% or poorly differentiated neuroendocrine carcinoma: less likely to be PRRT-eligible; your team will usually explore other options first

The article on PRRT for high-grade GEP-NETs covers the eligibility question for grade 3 tumors in more detail, including what current evidence shows for this group.

Kidney and blood function. The kidneys filter part of the radioactive compound used in PRRT and get some radiation exposure during each cycle. Borderline kidney function or low blood counts after prior chemotherapy may need to be addressed before treatment can start safely. The review team will flag this if your recent blood panel is part of what you share.

What If the Review Finds You Are Not Eligible?

This question deserves a direct answer. Sometimes a remote review finds that PRRT is not the right step right now. This can happen because of low somatostatin receptor expression, a high Ki-67 grade, borderline organ function, or a recent shift in disease behavior shown by newer imaging. In some cases, eligibility may improve after a period of stabilization or restaging - you may become eligible later.

A good review does not simply say no. It explains what the issue is and points toward alternatives worth discussing with your oncologist - whether that is adjusting somatostatin analogue therapy, a targeted agent, a clinical trial, or watchful waiting. If you want a review that explicitly addresses what else may be possible if PRRT is not appropriate, you can send your scans to the Art of Healing Cancer team for review - they assess DOTATATE eligibility and, where PRRT is not the right fit, can advise on other evidence-based options for your case.

For a broader look at what the treatment pathway can look like when PRRT is not an option, the article on GEP-NET second-line therapy when PRRT is not an option covers the main alternatives in detail.

After a Positive Review - What Comes Next?

If the remote review suggests PRRT is a reasonable next step, the path forward is fairly clear. Share the written review with your home oncologist and use it as the starting point for your next appointment. Then set up a teleconsultation with the treating center in India to agree on a timeline, discuss cycle spacing, and ask practical questions about travel and what to bring.

You will still need an in-person pre-treatment assessment when you arrive - fresh blood draws, review of recent imaging, and renal dosimetry - before the first cycle begins. You cannot do this step remotely. Most PRRT protocols use four cycles spaced roughly eight weeks apart, consistent with the standard lutetium Lu-177 dotatate protocol. Some international patients stay in India for the full course; others return home between cycles. The decision depends on travel cost, your health during treatment, and practical matters.

The gap between submitting scans and receiving a written review - typically five to fourteen working days - can feel long. Many GEP-NET patients notice disturbed sleep and heightened worry during this period. While the clinical plan is what matters most, some patients find it helpful to address sleep disruption during the waiting period. Your GP may have suggestions for you.

If you are ready to begin, you can submit your DOTATATE-PET report and pathology results for a remote eligibility review through the Lutetium Therapy contact form. If the review suggests PRRT is not currently the right fit, the team can offer a second opinion on what alternative next steps may be worth exploring.

When to Talk to Your Doctor

Talk to your oncologist before requesting a remote review if your disease has progressed recently, your health has changed significantly, or your most recent imaging is more than six months old. A remote review is only as good as the documents you provide. Outdated scans or blood results limit what the reviewing team can tell you.

Talk to your oncologist after receiving the written review as well. A second opinion is most valuable when you discuss it with your team.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What scans do I need for a remote PRRT eligibility review?

The most important scan is a Ga-68 DOTATATE PET/CT - this shows whether your tumor has somatostatin receptors and how strongly they express. A detailed radiology report with SUVmax values and a Krenning score is sufficient if you cannot share the full DICOM image files. Your pathology report with Ki-67 grade, a recent contrast CT or MRI, and a recent blood panel covering kidney and liver function round out a complete submission. You do not need all of these to start - the DOTATATE PET report and pathology report are enough for an initial read.

Can I get a remote PRRT review if I have not yet had a Ga-68 DOTATATE PET scan?

A team can give you a preliminary opinion based on older OctreoScan or Indium-111 scintigraphy results, but the Ga-68 DOTATATE PET is the current standard required before any PRRT centre will commit to treating you. It is far more sensitive than older scanning methods. If you cannot access a Ga-68 DOTATATE PET locally, the review team can advise on where the nearest scan centre is, what the scan typically costs, and whether any interim imaging approaches are available in your region.

What does the Krenning score on my DOTATATE PET mean for PRRT eligibility?

The Krenning score runs from 0 to 4. It grades how strongly your tumor absorbs the DOTATATE tracer compared to normal body tissues. A score of 0 or 1 means low or absent uptake - typically not eligible for PRRT. A score of 2 means uptake roughly equal to normal liver tissue, which is borderline by most guidelines. A score of 3 or 4, where uptake is clearly stronger than liver, is what most experienced PRRT centres prefer to see before proceeding. A score of 2 does not automatically rule you out; the full clinical picture matters, and a remote review can help interpret it in context.

How long does a remote PRRT eligibility review usually take?

Most experienced teams provide a first-pass written opinion within five to seven working days of receiving your scan report and pathology results. A more thorough multi-disciplinary review - where the case is discussed across nuclear medicine, oncology, and gastroenterology - may take ten to fourteen working days. If your documents are complete and recent, the turnaround is generally at the faster end of that range.

If the review says I am not eligible for PRRT right now, what happens next?

A thorough review should not just give a yes or no - it should explain the reason and, where possible, suggest what alternatives may be worth discussing with your oncologist. For some patients, eligibility may improve after a period of restaging or after adjusting prior treatment. For others, alternative therapies such as somatostatin analogues, targeted agents, or clinical trials may be the more appropriate path. The review team should also make clear whether the finding is likely to be permanent or potentially revisable with time.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PRRT Second Opinion Online: DOTATATE Eligibility India | lutetium-therapy